section name header

Pronunciation

MAN-i-tol

Classifications

Therapeutic Classification: cystic fibrosis therapy adjuncts, mucolytic

Indications

REMS


Action

  • Mechanism in improving pulmonary function in patients with cystic fibrosis is unknown.
Therapeutic effects:
  • Improvement in FEV1.

Pharmacokinetics

Absorption: Extent of absorption following oral inhalation unknown.

Distribution: Unknown.

Metabolism/Excretion: Excreted by the kidneys; minimal liver metabolism.

Half-Life: 4.7 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
Inhalationunknown1.5 hrUnknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: oropharyngeal pain

GI: vomiting

MS: arthralgia

Resp: cough, hemoptysis, bronchospasm

Misc: fever

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Bronchitol

Code

NDC Code